Standard

What minor KRAS mutations should be analyzed in colorectal cancer? / Fomin, Ivan N.; Kovalenko, Sergei P.

In: Voprosy Onkologii, Vol. 71, No. 1, 13, 2025, p. 136-142.

Research output: Contribution to journal › Article › peer-review

Harvard

Fomin, IN & Kovalenko, SP 2025, 'What minor KRAS mutations should be analyzed in colorectal cancer?', Voprosy Onkologii, vol. 71, no. 1, 13, pp. 136-142. https://doi.org/10.37469/0507-3758-2025-71-1-OF-2188

APA

Fomin, I. N., & Kovalenko, S. P. (2025). What minor KRAS mutations should be analyzed in colorectal cancer? Voprosy Onkologii, 71(1), 136-142. [13]. https://doi.org/10.37469/0507-3758-2025-71-1-OF-2188

Vancouver

Fomin IN, Kovalenko SP. What minor KRAS mutations should be analyzed in colorectal cancer? Voprosy Onkologii. 2025;71(1):136-142. 13. doi: 10.37469/0507-3758-2025-71-1-OF-2188

Author

Fomin, Ivan N. ; Kovalenko, Sergei P. / What minor KRAS mutations should be analyzed in colorectal cancer?. In: Voprosy Onkologii. 2025 ; Vol. 71, No. 1. pp. 136-142.

BibTeX

@article{88dd73470f364b9d9a22365d2c2644ca,
title = "What minor KRAS mutations should be analyzed in colorectal cancer?",
abstract = "The selection of minor mutations in the KRAS gene proposed for analysis in colorectal cancer patients prior to anti-EGFR treatment is discussed in the context of the available clinical data. It is shown that, to date, there are no clear results from clinical trials demonstrating the clinical significance of all known mutations in codons 59, 61, 117, 146 of the KRAS gene in colorectal cancer. Only those KRAS mutations for which analysis is fully justified by clinical data are proposed for inclusion in the list of mutations recommended for analysis in the clinic. In conclusion, the analysis of mutations prior to anti-EGFR therapy has no statistically significant clinical justification for mutations A146V, A146P and is not justified for all mutations in codon 59 of the KRAS gene.",
keywords = "KRAS gene, colorectal cancer, minor mutations, колоректальный рак, ген KRAS, минорные мутации",
author = "Fomin, {Ivan N.} and Kovalenko, {Sergei P.}",
note = "Фомин И.Н., Коваленко С.П. Какие минорные мутации необходимо анализировать в гене KRAS в клетках опухоли при колоректальном раке? // Вопросы онкологии. - 2025. - Т. 71. - № 1. - № OF–2188.",
year = "2025",
doi = "10.37469/0507-3758-2025-71-1-OF-2188",
language = "English",
volume = "71",
pages = "136--142",
journal = "Voprosy Onkologii",
issn = "0507-3758",
publisher = "Izdatelstvo Meditsina",
number = "1",

}

RIS

TY - JOUR

T1 - What minor KRAS mutations should be analyzed in colorectal cancer?

AU - Fomin, Ivan N.

AU - Kovalenko, Sergei P.

N1 - Фомин И.Н., Коваленко С.П. Какие минорные мутации необходимо анализировать в гене KRAS в клетках опухоли при колоректальном раке? // Вопросы онкологии. - 2025. - Т. 71. - № 1. - № OF–2188.

PY - 2025

Y1 - 2025

N2 - The selection of minor mutations in the KRAS gene proposed for analysis in colorectal cancer patients prior to anti-EGFR treatment is discussed in the context of the available clinical data. It is shown that, to date, there are no clear results from clinical trials demonstrating the clinical significance of all known mutations in codons 59, 61, 117, 146 of the KRAS gene in colorectal cancer. Only those KRAS mutations for which analysis is fully justified by clinical data are proposed for inclusion in the list of mutations recommended for analysis in the clinic. In conclusion, the analysis of mutations prior to anti-EGFR therapy has no statistically significant clinical justification for mutations A146V, A146P and is not justified for all mutations in codon 59 of the KRAS gene.

AB - The selection of minor mutations in the KRAS gene proposed for analysis in colorectal cancer patients prior to anti-EGFR treatment is discussed in the context of the available clinical data. It is shown that, to date, there are no clear results from clinical trials demonstrating the clinical significance of all known mutations in codons 59, 61, 117, 146 of the KRAS gene in colorectal cancer. Only those KRAS mutations for which analysis is fully justified by clinical data are proposed for inclusion in the list of mutations recommended for analysis in the clinic. In conclusion, the analysis of mutations prior to anti-EGFR therapy has no statistically significant clinical justification for mutations A146V, A146P and is not justified for all mutations in codon 59 of the KRAS gene.

KW - KRAS gene

KW - colorectal cancer

KW - minor mutations

KW - колоректальный рак

KW - ген KRAS

KW - минорные мутации

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85219517509&origin=inward&txGid=af2428d39b42423d31a06ec2b3188888

UR - https://www.mendeley.com/catalogue/e7d3bb66-eca3-3314-96d7-8f71627cd90d/

U2 - 10.37469/0507-3758-2025-71-1-OF-2188

DO - 10.37469/0507-3758-2025-71-1-OF-2188

M3 - Article

VL - 71

SP - 136

EP - 142

JO - Voprosy Onkologii

JF - Voprosy Onkologii

SN - 0507-3758

IS - 1

M1 - 13

ER -

ID: 64991328